asolfena 10 mg
krka, d.d., novo mesto, slovinsko - solifenacín - 73 - spasmolytica
rosuvastatin mylan 5 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 10 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 20 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 40 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
prezista
janssen-cilag international nv - darunavir - hiv infekcie - antivirotiká na systémové použitie - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.
jodid draselný 65 hameln
hameln rds s. r. o., slovensko - jodid draselný - 19 - antidota, detoxicantia
tiaprid pmcs 100 mg
pro.med.cs praha a.s., Česká republika - tiaprid - 68 - antipsychotica (neuroleptica)
flucelvax tetra
seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - chrípka, človek - chrípka, inaktivované, split vírus alebo povrchových antigénov - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra by mali byť použité v súlade s oficiálne odporúčania.
deferasirox accord
accord healthcare s.l.u. - deferasirox - iron overload; beta-thalassemia - všetky ostatné terapeutické výrobky, Železo chelatačné činidlá - deferasirox dohode je indikovaný na liečbu chronického preťaženia železom vzhľadom na časté krvné transfúzie (≥7 ml/kg/mesiac balené červených krviniek) u pacientov s beta thalassaemia major vo veku 6 rokov a starších. deferasirox dohode je taktiež indikovaný na liečbu chronického preťaženia železom v dôsledku krvnej transfúzie, ak deferoxamínu terapia je kontraindikovaný alebo je nedostatočné v týchto skupín pacientov:v pediatrických pacientov s beta thalassaemia hlavných s preťaženia železom vzhľadom na časté krvné transfúzie (≥7 ml/kg/mesiac balené červených krviniek) vo veku 2 až 5 rokov,u dospelých a pediatrických pacientov s beta thalassaemia hlavných s preťaženia železom kvôli zriedkavé krvné transfúzie (.